Table 3. Univariate and multivariate COX regression analyses of clinical factors and independence associated with prognosis.
Variables | Univariate analysis | Multivariable analysis | ||||
HR | 95%CI of HR | P | HR | 95%CI of HR | P | |
TCGA training datasets | ||||||
6-gene risk score | ||||||
Low risk group | 1(reference) | 1(reference) | ||||
High risk group | 2.66 | 1.79-3.92 | 1.060E-06 | 2.18 | 1.04-4.53 | 0.038 |
Age | 1.03 | 1.01-1.04 | 8.550E-04 | 0.99 | 0.95-1.02 | 0.604231 |
Gender female | 1(reference) | 1(reference) | ||||
Gender male | 0.73 | 0.49- 1.07 | 0.11 | 0.50 | 0.23-1.09 | 0.081554 |
Grade 1 | 1(reference) | 1(reference) | ||||
Grade 2 | 1.78 | 0.95-3.32 | 0.07 | 0.91 | 0.25-3.18 | 0.88025 |
Grade 3 / 4 | 1.47 | 0.75-2.87 | 0.26 | 1.94 | 0.53-7.04 | 0.315185 |
Pathologic T 1/ T 2 | 1(reference) | 1(reference) | ||||
Pathologic T 3 | 2.26 | 1.28-3.95 | 4.53E-03 | 2.07 | 0.51-8.37 | 0.309 |
Pathologic T 4 | 2.46 | 1.50-4.00 | 3.19E-04 | 7.59 | 1.90-30.22 | 0.004 |
Pathologic N 0 | 1(reference) | 1(reference) | ||||
Pathologic N 1 | 0.89 | 0.37-2.08 | 0.782 | 0.76 | 0.19-3.01 | 0.694 |
Pathologic N 2 | 2.29 | 1.40-3.72 | 0.001 | 5.02 | 1.97-12.75 | 0.001 |
Pathologic M 0 | 1(reference) | 1(reference) | ||||
Pathologic M 1/ M X | 1.31 | 0.66-2.55 | 0.433 | 1.16 | 0.43-3.08 | 0.76 |
Tumor stage I | 1(reference) | 1(reference) | ||||
Tumor stage II | 1.08 | 0.23-4.90 | 0.918 | 0.55 | 0.03-9.85 | 0.686335 |
Tumor stage III | 1.40 | 0.30-6.42 | 0.667 | 0.77 | 0.05-10.60 | 0.845959 |
Tumor stage IV | 2.75 | 0.67-11.22 | 0.158 | 0.27 | 0.02-3.63 | 0.32 |
Validation cohort, TCGA test datasets and GSE65858 | ||||||
TCGA test datasets | ||||||
6-gene risk score | ||||||
Low risk group | 1(reference) | 1(reference) | ||||
High risk group | 1.62 | 1.08- 2.42 | 0.020 | 1.45 | 0.67-3.12 | 0.339 |
Age | 1.01 | 0.98-1.02 | 0.444 | 1.00 | 0.96-1.03 | 0.993 |
Gender female | 1(reference) | 1(reference) | ||||
Gender male | 0.84 | 0.55-1.28 | 0.420 | 0.45 | 0.19-1.01 | 0.054 |
Grade 1 | 1(reference) | 1(reference) | ||||
Grade 2 | 1.86 | 0.92-3.77 | 0.08 | 0.90 | 0.28-2.88 | 0.865 |
Grade 3 | 1.57 | 0.73-3.36 | 0.24 | 1.54 | 0.42-5.52 | 0.508 |
Pathologic T 1/ T 2 | 1(reference) | 1(reference) | ||||
Pathologic T 3 | 1.84 | 1.09-3.11 | 0.022 | 1.76 | 0.47-6.54 | 0.399 |
Pathologic T 4 | 1.36 | 0.84-2.21 | 0.213 | 1.20 | 0.35-4.07 | 0.770 |
Pathologic N 0 | 1(reference) | |||||
Pathologic N 1 | 1.14 | 0.57-2.25 | 0.706 | 1.74 | 0.50-6 | 0.379 |
Pathologic N 2 | 2.49 | 1.50-4.12 | 0.000 | 1.87 | 0.65-5.32 | 0.239 |
Pathologic N 3 | 2.90 | 0.87-9.6 | 0.082 | 1.86 | 0.26-12.82 | 0.529 |
Pathologic M 0 | 1(reference) | 1(reference) | ||||
Pathologic M 1 | 1.05 | 0.49-2.21 | 0.905 | 1.34 | 0.54-3.28 | 0.524 |
Tumor stage I | 1(reference) | |||||
Tumor stage II | 2.94 | 0.34-0.66 | 0.157 | 0.55 | 0.03-9.20 | 0.677 |
Tumor stage III | 3.04 | 0.32-0.70 | 0.137 | 1.00 | 0.08-11.42 | 0.997 |
Tumor stage IV | 4.03 | 0.24-0.98 | 0.053 | 1.46 | 0.12-17.69 | 0.765 |
GSE65858 | ||||||
6-gene risk score | ||||||
Low risk group | 1(reference) | 1(reference) | ||||
High risk group | 1.75 | 1.13-2.67 | 0.011 | 1.83 | 1.16-2.87 | 0.008 |
Age | 1.03 | 1.00-1.04 | 0.01 | 1.03 | 1.01-1.05 | 0.00 |
Gender female | 1(reference) | 1(reference) | ||||
Gender male | 1.05 | 0.61-1.77 | 0.87 | 1.02 | 0.59-1.75 | 0.94 |
Pathologic T 1 | 1(reference) | 1(reference) | ||||
Pathologic T 2 | 0.49 | 0.21-1.15 | 0.10 | 0.53 | 0.15-1.78 | 0.31 |
Pathologic T 3 | 1.73 | 0.81-3.67 | 0.15 | 1.61 | 0.55-4.69 | 0.38 |
Pathologic T 4 | 1.89 | 0.91-3.87 | 0.08 | 1.22 | 0.42-3.53 | 0.71 |
Pathologic N 0 | 1(reference) | 1(reference) | ||||
Pathologic N 1 | 0.36 | 0.12-1.02 | 0.06 | 0.34 | 0.10-1.08 | 0.07 |
Pathologic N 2 | 1.60 | 0.99-2.56 | 0.05 | 1.03 | 0.51-2.05 | 0.94 |
Pathologic N 3 | 2.93 | 1.34-6.42 | 0.01 | 1.27 | 0.41-3.84 | 0.67 |
Pathologic M 0 | 1(reference) | 1(reference) | ||||
Pathologic M 1/ M X | 3.71 | 1.63-8.4 | 0.00 | 2.18 | 0.70-6.79 | 0.18 |
Tumor stage I | 1(reference) | 1(reference) | ||||
Tumor stage II | 0.39 | 0.11-1.33 | 0.13 | 0.60 | 0.10-3.40 | 0.56 |
Tumor stage III | 0.46 | 0.14-1.45 | 0.19 | 0.66 | 0.13-3.31 | 0.61 |
Tumor stage IV | 1.49 | 0.60-3.70 | 0.39 | 1.14 | 0.24-5.20 | 0.87 |